JBIO today
$16.54+$0.14 (+0.85%)close Nov 11, 2026Trend
DailyUptrend (confirmed)
4 hourSymmetric Triangle
1 hourLeaning Bearish
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns down below $12.52
Key levels
Resistance$19.02
Resistance$17.50
Support$16.44
Support$15.19
Latest news & SEC filings
AnalystAnalyst Keeps Buy Rating on Jade Biosciences, $77 Target Unchanged
All JBIO news →About Jade Biosciences
Jade Biosciences is a clinical-stage biopharmaceutical company that develops biologic therapies for autoimmune diseases. Its lead candidate, JADE101, is an antibody targeting APRIL that is being developed for IgA nephropathy, with a second candidate, JADE201, targeting BAFF-R for multiple autoimmune disorders and a third program, JADE301, aimed at an undisclosed pathway. The company's therapies are intended for patients with autoimmune conditions such as IgA nephropathy and rheumatoid arthritis, and its clinical activities take place in New Zealand.
Based on the company's 10-K filed Mar 6, 2026.
Nasdaq · Healthcare
Jade Biosciences, Inc. (JBIO)
What Is the Price Target for JBIO?
SEPT Low Target
$32.00
SEPT Mid Target
$45.00
SEPT High Target
$77.00
Analyst Consensus
$45.00
Is JBIO a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for JBIO.
Start Free Trial →Is JBIO Overvalued or Undervalued?
Valuation Verdict
FAIR
Methods Used
PEG, Analyst Consensus
Fair Value
$31.12
12
Moat Score
NONE
4/9
Piotroski Score
15.3
Altman Z-Score
What Is Smart Money Doing with JBIO?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →JBIO Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-30.74%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for JBIO
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for JBIO, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:07 | $16.54 | 2,814 | $$47K | BUY |
| 21:00:07 | $16.54 | 1,938 | $$32K | BUY |
| 21:00:07 | $16.54 | 2,928 | $$48K | BUY |
| 21:00:00 | $16.54 | 1,700 | $$28K | SELL |
| 20:55:02 | $16.48 | 3,800 | $$63K | MIDPOINT |
5 dark pool trades shown · $$218K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Jade Biosciences, Inc. (JBIO) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →JBIO — frequently asked questions
What is JBIO stock price today?
Jade Biosciences, Inc. (JBIO) is at $16.54, up 0.85% (+$0.14) at the Nov 11, 2026 close.
Why is JBIO stock moving today?
Latest JBIO news — Oct 27, 2026: Analyst Keeps Buy Rating on Jade Biosciences, $77 Target Unchanged
What is the JBIO price target?
The average analyst price target for JBIO is $45.00, ranging from $32 to $77, based on 6 analysts.
What do analysts rate JBIO?
Analyst ratings for JBIO: 0 Buy, 11 Hold, 0 Sell — consensus Hold.
Did JBIO beat earnings?
JBIO last reported on Aug 10, 2026: EPS -$0.76 vs -$0.64 expected — a miss of 19.4%.
What is JBIO's P/E ratio?
JBIO trades at a P/E of 1.8 vs a Healthcare average of 18.5.
Does JBIO pay a dividend?
Yes. JBIO's dividend yield is 15.55%.
What are JBIO support and resistance levels?
Support: $16.44, $15.19, $13.65. Resistance: $17.50, $19.02, $20.35.
What are insiders doing with JBIO?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on JBIO?
Oct 27, 2026: Analyst Keeps Buy Rating on Jade Biosciences, $77 Target Unchanged